Breaking News, Collaborations & Alliances

Ligand Earns SAGE Milestone

SAGE-547 enters clinical development

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Ligand Pharmaceuticals Inc. has earned a $150,000 milestone payment from SAGE Therapeutics (SAGE) related to the initiation of a Phase 1/2 trial of SAGE-547 for the treatment of super-refractory status epilepticus (SRSE), a life-threatening seizure condition.   SAGE-547 is an intravenous agent that utilizes Ligand’s Captisol technology. Ligand and SAGE entered a platform license agreement in 2013 for the development and commercialization of Captisol-enabled therapeutics for a broad range of debi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters